Growing evidence supports cannabis-based medicine for Tourette syndrome tics and comorbidities
A review of cannabis-based treatments for Tourette syndrome found growing evidence of efficacy for tics and psychiatric comorbidities, with two small RCTs demonstrating THC safety and efficacy, though larger trials are still needed.
Quick Facts
What This Study Found
Two small RCTs using THC (dronabinol) demonstrated safety and efficacy for tic treatment in Tourette syndrome. However, a trial of the endocannabinoid modulator Lu AG06466 failed. Current guidelines classify cannabis-based treatment as experimental for treatment-resistant patients.
Key Numbers
Two published RCTs using THC/dronabinol showed safety and efficacy. One RCT of Lu AG06466 (endocannabinoid modulator) was negative. Both AAN and ESSTS guidelines classify cannabis treatment as experimental. Larger RCT (CANNA-TICS) is ongoing.
How They Did This
Two reviewers searched PubMed for studies on cannabis/cannabinoid treatment of Tourette syndrome. Included case reports, case series, open uncontrolled studies, and RCTs. Reviewed evidence for tic reduction and comorbidity management.
Why This Research Matters
Tourette syndrome has limited treatment options, and many patients experience intolerable side effects from antipsychotics. Cannabis-based treatments represent a potential alternative for treatment-resistant patients.
The Bigger Picture
While most evidence comes from case reports and small studies, the two positive RCTs and the ongoing CANNA-TICS trial suggest cannabis-based medicine may eventually join the standard treatment toolkit for Tourette syndrome.
What This Study Doesn't Tell Us
Majority of evidence is from case reports and uncontrolled studies. The two positive RCTs were small. Cannabis-based treatment remains experimental by guideline standards. The failed endocannabinoid modulator trial complicates the picture.
Questions This Raises
- ?Will the CANNA-TICS trial confirm earlier positive findings?
- ?Why did the endocannabinoid modulator fail while THC succeeded?
- ?Would CBD alone or CBD:THC combinations be more effective or better tolerated?
Trust & Context
- Key Stat:
- Two RCTs showed THC safe and effective for tics
- Evidence Grade:
- Moderate: includes two positive RCTs, but most evidence is from lower-quality study designs and sample sizes are small.
- Study Age:
- Published in 2022.
- Original Title:
- Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome.
- Published In:
- Neurologia i neurochirurgia polska, 56(1), 28-38 (2022)
- Authors:
- Szejko, Natalia(8), Saramak, Kamila(2), Lombroso, Adam, Müller-Vahl, Kirsten
- Database ID:
- RTHC-04253
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is cannabis approved for Tourette syndrome?
No. Both the American Academy of Neurology and the European Society for the Study of Tourette Syndrome classify cannabis-based treatment as experimental, recommended only for treatment-resistant patients.
What form of cannabis showed benefit?
The two positive RCTs used THC (dronabinol). Other forms (whole-plant, nabiximols) have been studied in smaller, uncontrolled settings with generally positive results.
Did cannabis help with more than just tics?
Yes. Evidence suggests cannabis-based medicine may also improve psychiatric comorbidities commonly seen in Tourette syndrome, such as OCD and anxiety, though this evidence is less robust.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04253APA
Szejko, Natalia; Saramak, Kamila; Lombroso, Adam; Müller-Vahl, Kirsten. (2022). Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome.. Neurologia i neurochirurgia polska, 56(1), 28-38. https://doi.org/10.5603/PJNNS.a2021.0081
MLA
Szejko, Natalia, et al. "Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome.." Neurologia i neurochirurgia polska, 2022. https://doi.org/10.5603/PJNNS.a2021.0081
RethinkTHC
RethinkTHC Research Database. "Cannabis-based medicine in treatment of patients with Gilles..." RTHC-04253. Retrieved from https://rethinkthc.com/research/szejko-2022-cannabisbased-medicine-in-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.